Genmab AS

Genmab AS EBIT per Share

The EBIT per Share of Genmab AS (GMAB) as of Nov 22, 2026 is 1.86 USD. In the previous year, EBIT per Share was 10.45 USD — a change of -82.20% (lower).

EBIT per Share

1.86USD

YoY

-82.20%

Last updated:

EBIT per Share of Genmab AS is 2025 1.86 USD. EBIT per Share of Genmab AS was 2024 10.45 USD. It decreases by -82.20% lower compared to the previous year.

The Genmab AS EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
8.09 USD
Jan 1, 2024
10.45 USD
Jan 1, 2025
1.86 USD
Jan 1, 2026 (e)
1.71 USD
Jan 1, 2027 (e)
2.01 USD
Jan 1, 2028 (e)
3.92 USD
Jan 1, 2029 (e)
3.76 USD
Jan 1, 2030 (e)
4.39 USD
The Genmab AS EBIT per Share history
YEAREBIT per ShareYoY
est4.39USD+16.86%
est3.76USD-4.24%
est3.92USD+95.47%
est2.01USD+17.23%
est1.71USD-7.97%
1.86USD-82.20%
10.45USD+29.18%
8.09USD-14.73%
9.49USD+112.46%
4.46USD-53.27%
9.55USD+138.25%
4.01USD+80.39%
2.22USD+2.92%
2.16USD+26.96%
1.70USD+38.45%
1.23USD+167.81%
0.46USD+252.77%
0.13USD-153.24%
-0.24USD-56.06%
-0.56USD+55.41%
-0.36USD-67.72%
-1.11USD-32.07%
-1.63USD+64.05%
-0.99USD-18.00%
-1.21USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genmab AS Stock analysis

What does Genmab AS do? Genmab AS is a biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. It develops and markets antibody-based therapies for cancer and other diseases, including EPKINLY, TEPKINLY, and Tivdak for various lymphomas and cervical cancer. The company also advances several product candidates in clinical development, such as Epcoritamab for lymphomas and GEN1059 for solid tumors, alongside established treatments like DARZALEX and TECVAYLI for multiple myeloma and other conditions. Genmab AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab AS stock

EBIT per Share of Genmab AS is 1.86 USD in 2025.

EBIT per Share of Genmab AS changed from 10.45 USD to 1.86 USD, representing a -82.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Genmab AS since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genmab AS

All Key Metrics — Genmab AS